Explore News
-
Next-Gen GLP-1 Drug Survodutide Shows 16% More Weight Loss Than Zepbound
A phase 3 trial reveals survodutide, a dual GLP-1 and glucagon receptor agonist, led to…
A phase 3 trial reveals survodutide, a dual GLP-1 and glucagon receptor agonist, led to…
